Rankings
▼
Calendar
KLRS Q2 2024 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena
KLRS
Kalaris Therapeutics Inc
$187M
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$4M
Net Income
-$6M
EPS (Diluted)
$-1.13
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$322,000
Balance Sheet
Total Assets
$131M
Total Liabilities
$11M
Stockholders' Equity
$120M
Cash & Equivalents
$105M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$4M
-$47M
+91.1%
Net Income
-$6M
-$45M
+87.5%
← FY 2024
All Quarters
Q3 2024 →